Insight

Jame Abraham: Glotiftamab combination shows safety and efficacy for relapsed large B-cell lymphoma

my.clevelandclinic.org

Dec 20, 2024, 10:22

Jame Abraham: Glotiftamab combination shows safety and efficacy for relapsed large B-cell lymphoma

Jame Abraham,Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post on X:

“Bispecific Antibody Glotiftamab Combination with Chemoimmunotherapy Safe and Effective for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy.”

More posts featuring Jame Abraham.

Jame Abraham, MD, FACP, is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He also is a Deputy Editor at the ASCO Post and Journal of Oncology Practice of ASCO.

Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee and holds leadership roles in NRG Oncology and the National Surgical Adjuvant Breast and Bowel Project (NSABP).

bispecific antibody Cancer research cancer treatment chemoimmunotherapy Cleveland Clinic Diffuse Large B-Cell Lymphoma Glotiftamab Jame Abraham Oncology relapsed cancer

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage